Invivyd vs Q32 Bio
Q32 Bio reported revenue of $54 million in fiscal 2025, about the same as Invivyd's $53 million in fiscal 2025. Invivyd had an operating margin of -104.0%, against 31.4% at Q32 Bio. Free cash flow was −$58 million at Invivyd and −$34 million at Q32 Bio.
Side by side
| Invivyd | Q32 Bio | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $53M | $54M |
| Revenue growth | 110.5% | — |
| Revenue growth a year, last 5 years | — | 81.9% |
| Gross margin | — | — |
| Operating margin | −104.0% | 31.4% |
| Net margin | −98.2% | 55.5% |
| Free cash flow | −$58M | −$34M |
| Free cash flow margin | −109.1% | −62.4% |
| Return on capital | — | — |
| Net debt to EBITDA | — | −2.8x |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 45.3% | 27.5% |
| Last close | $0.45 | $8.48 |
| P/E at the last close | — | 10.5× |
| Insider trades, last 12 months | sold $341,120 | — |
| Piotroski F-score | — | 3 of 8 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
InvivydQ32 Bio
Operating margin
Percent of revenue
InvivydQ32 Bio
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
InvivydQ32 Bio